author-photo

Hidemi Nakagawa

Jikei University School of Medicine

344

Papers

6399

Citations

Citation Trend

Filter By

Papers (344) Sort By

JournalConferenceOthers

Certolizumab Pegol for the Treatment of Moderate to Severe Plaque Psoriasis: 16-Week Results from a Phase 2/3 Japanese Study.

2021 Dermatologic Therapy
Show All
- Source
- Cite
- Save
Citations (2)
25094 Delgocitinib ointment in pediatric patients with atopic dermatitis: A phase 3, randomized, double-blind, vehicle-controlled study and an open-label, long-term extension study

2021 Journal of The American Academy of Dermatology
Show All
- Source
- Cite
- Save
Citations (1)
Certolizumab Pegol in Japanese Patients with Moderate to Severe Plaque Psoriasis: Effect of Demographics and Baseline Disease Characteristics on Efficacy.

2021 Dermatologic Therapy
Show All
- Source
- Cite
- Save
Citations (0)
Characteristics of anti-IL-17/23 biologics-induced interstitial pneumonia in patients with psoriasis

2021 PLOS ONE
Show All
- Source
- Cite
- Save
Citations (1)
Efficacy and Safety of Calcipotriol Plus Betamethasone Dipropionate Foam in Japanese Patients with Psoriasis Vulgaris : A Phase III Study

2021 Nishi Nihon Hifuka
Show All
- Source
- Cite
- Save
Citations (0)
Effect of anti-interleukin-17 biologics on Krebs von den Lungen-6 level in patients with psoriasis.

2021 Journal of Dermatology
Show All
- Source
- Cite
- Save
Citations (0)
Delgocitinib ointment in pediatric patients with atopic dermatitis: A phase 3, randomized, double-blind, vehicle-controlled study and a subsequent open-label, long-term study.

2021 Journal of The American Academy of Dermatology
Show All
- Source
- Cite
- Save
Citations (4)
Efficacy and Safety of Certolizumab Pegol in Japanese Patients with Moderate to Severe Plaque Psoriasis: 52-Week Results.

2021 Dermatologic Therapy
Show All
- Source
- Cite
- Save
Citations (1)
Efficacy and safety of tildrakizumab in Japanese patients with moderate to severe plaque psoriasis: Results from a 64-week phase 3 study (reSURFACE 1).

2021 Journal of Dermatology
Show All
- Source
- Cite
- Save
Citations (0)
Long-term efficacy and safety of tildrakizumab in Japanese patients with moderate to severe plaque psoriasis: Results from a 5-year extension of a phase 3 study (reSURFACE 1).

2021 Journal of Dermatology
Show All
- Source
- Cite
- Save
Citations (0)

© Copyright 2015-2020 Acemap, Inc. Shanghai Jiao Tong University.

沪ICP备18028330号